240
Participants
Start Date
January 8, 2014
Primary Completion Date
December 11, 2018
Study Completion Date
December 11, 2018
Insulin (Humulin® R U-100)
20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
Placebo
Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
Mount Sinai School of Medicine, New York
University of Rochester Medical Center, Rochester
Georgetown University, Washington D.C.
Howard University, Washington D.C.
Johns Hopkins University, Baltimore
Wake Forest University Health Sciences, Winston-Salem
Roper St. Francis Hospital, Charleston
Emory University, Atlanta
Mayo Clinic, Jacksonville, Jacksonville
University of Kentucky, Lexington
Case Western Reserve University, Beachwood
Indiana University, Indianapolis
Mayo Clinic, Rochester, Rochester
Northwestern University, Chicago
Rush University Medical Center, Chicago
Tulsa Clinical Research, Tulsa
Baylor College of Medicine, Houston
Banner Alzheimer's Institute, Phoenix
Barrow Neurology Clinics, Phoenix
University of California, Irvine, Irvine
U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle
Yale University School of Medicine, New Haven
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Rhode Island Hospital, Providence
Collaborators (1)
National Institute on Aging (NIA)
NIH
Alzheimer's Therapeutic Research Institute
OTHER
Wake Forest University Health Sciences
OTHER
University of Southern California
OTHER